Efficacy and Safety of Insulin Glargine 300 U/mL versus Insulin Glargine 100 U/mL in Asia Pacific Insulin-Naïve People with Type 2 Diabetes: The EDITION AP Randomised Controlled Trial.
To compare the efficacy and safety of Gla-300 versus Gla-100 in insulin-naïve people with type 2 diabetes mellitus (T2DM) in Asia Pacific. In this open-label, randomised, active-controlled, 26-week study, insulin-naïve participants with T2DM inadequately controlled with non-insulin antihyperglycaemic drugs were randomised (2:1) to Gla-300 or Gla-100. The initial daily dose of basal insulin was 0.2 U/kg and adjusted at least weekly for 8-12 weeks to a target fasting self-monitored plasma glucose (SMPG) of 4.4-5.6 mmol/L. Of the 604 participants randomised, 570 (Gla-300 n=375; Gla-100 n=195) completed the study. Non-inferiority of Gla-300 versus Gla-100 in HbA1c reduction from baseline to week 26 was confirmed. In the Gla-300 and Gla-100 groups, 51.1% and 52.2% of participants achieved HbA1c target <7.0% (rate ratio [95% CI]: 0.98 [0.84 to 1.14]) and 19.1% and 21.9% achieved target without hypoglycaemia during the last 12 weeks of treatment (rate ratio [95% CI]: 0.87 [0.63 to 1.20]). Changes in fasting plasma glucose and 24-hour average 8-point SMPG were comparable between groups. Incidence of hypoglycaemia at any time of day was similar between treatment groups at Week 26, but incidence of anynocturnal hypoglycaemia were numerically lower with Gla-300 than Gla-100 over the initial 12-week titration period and 26-week on-treatment period. Rates of adverse events were similar between groups and low for serious adverse events. Glycaemic control of Gla-300 is non-inferior to Gla-100 with a similar or lower incidence and proportion of hypoglycaemia in people with T2DM in Asia Pacific, reinforcing the results in the global EDITION programme. This article is protected by copyright. All rights reserved.